Tumor Vaccines for Malignant Melanoma: Progress, Challenges, and Future Directions

Malignant melanoma, characterized by its high metastatic potential and resistance to conventional therapies, presents a major challenge in oncology. This review explores the current status and advancements in tumor vaccines for melanoma, focusing on peptide, DNA/RNA, dendritic cell, tumor cell, and neoantigen-based vaccines. Despite promising results, significant challenges remain, including the immunosuppressive tumor microenvironment, patient heterogeneity, and the need for more effective antigen presentation. Recent strategies, such as combining vaccines with immune checkpoint inhibitors (ICIs), aim to counteract immune evasion and enhance T cell responses. Emerging approaches, including personalized neoantigen vaccines and the use of self-amplifying RNA platforms, hold promise for overcoming tumor heterogeneity and improving vaccine efficacy. Additionally, optimizing vaccine delivery systems through nanotechnology and genetic modifications is essential for increasing stability and scalability. This review highlights the potential of these innovative strategies to address current limitations, with a focus on how future research can refine and combine these approaches to improve melanoma treatment outcomes.